Cabergoline use for pituitary tumors and valvular disorders

Endocrinol Metab Clin North Am. 2015 Mar;44(1):89-97. doi: 10.1016/j.ecl.2014.10.007. Epub 2014 Nov 4.

Abstract

Cabergoline (CAB) is widely used for the medical treatment of pituitary tumors, particularly those associated with hormone hypersecretion. Whether treatment with CAB is associated with an increased risk of clinically relevant cardiac valve disease in patients with pituitary tumors is still debated. In most studies, CAB has been found not associated with an increased risk of significant valvulopathy, and no correlation has been shown between valvular abnormalities and CAB duration or cumulative dose. This review provides an overview of the studies reporting on the outcome of CAB in terms of cardiac valve disease in patients with pituitary tumors.

Keywords: Acromegaly; Cabergoline; Cardiac valve disease; Cushing’s disease; Dopamine-agonists; Pituitary adenoma; Prolactinoma.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Acromegaly / drug therapy*
  • Cabergoline
  • Dopamine Agonists / administration & dosage
  • Dopamine Agonists / adverse effects*
  • Dopamine Agonists / pharmacology
  • Ergolines / administration & dosage
  • Ergolines / adverse effects*
  • Ergolines / pharmacology
  • Heart Valve Diseases / chemically induced*
  • Humans
  • Pituitary Neoplasms / drug therapy*
  • Prolactinoma / drug therapy*

Substances

  • Dopamine Agonists
  • Ergolines
  • Cabergoline